Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Combining TKIs with checkpoint inhibitors for prostate cancer – is this the way forward?

Simon Chowdury, MD, PhD, from the Sarah Cannon Research Institute, London, UK, talks to us about the undesirable outcomes from research on combining immune checkpoint inhibitors with tyrosine kinase inhibitors (TKIs) for the treatment of prostate cancer, namely hepatoxicity. Although disappointing, he notes that there is still potential for combination therapy in treating prostate cancer. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.